RxDoctor Payments DataLook up a doctor →

Maria Garcia Pallas, MD

Hematology & Oncology · Caguas, PRNPI 1720019912

Payments from drug & device makers

$1,791,061in general payments, 2019–2025

Across 968 payments — averaging $1850.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$547K
  • Takeda Pharmaceuticals U.S.A., Inc.$492K
  • Boehringer Ingelheim$319K
  • Bristol Myers Squibb$142K
  • E.r. Squibb & Sons, L.L.C.$110K
  • AstraZeneca$77K
  • plus $105K from 45 others

What the payments were for

  • Consulting fees$33,89047%
  • Speaking & faculty fees$21,99330%
  • Travel & lodging$9721%
  • Food & beverage$15,17221%
  • Education$4431%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,791,061 in reported general payments places this provider in the 95th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,045
Medicare patients
26
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SprycelDasatinib79$1,350,642
PromactaEltrombopag Olamine39$726,737
IdhifaEnasidenib Mesylate15$520,121
VenclextaVenetoclax48$446,519
IbrancePalbociclib16$260,745
CalquenceAcalabrutinib Maleate17$251,543
RevlimidLenalidomide13$235,294
KisqaliRibociclib Succinate13$232,449
InlytaAxitinib14$170,342
BosulifBosutinib13$63,586
Abiraterone Acetate18$36,386
Tretinoin12$32,654
RetacritEpoetin Alfa-Epbx15$16,663
XareltoRivaroxaban15$8,625
Hydroxyurea24$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sprycel$109,672$1,350,64279 claims
NovartisPromacta, Kisqali$446$959,18652 claims
Bristol Myers SquibbIdhifa, Revlimid$142,070$755,41428 claims
PfizerIbrance, Inlyta, Bosulif, Retacrit$19,070$511,33658 claims
AbbVieVenclexta, Synthroid$546,804$447,35265 claims
AstraZenecaCalquence$77,091$251,54317 claims
Johnson & JohnsonXarelto$4,061$8,62515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →